Abivax SA American Depositary Shares (ABVX) - Total Assets
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) holds total assets worth $547.14 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ABVX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Abivax SA American Depositary Shares - Total Assets Trend (2013–2025)
This chart illustrates how Abivax SA American Depositary Shares's total assets have evolved over time, based on quarterly financial data. See ABVX net asset value for net asset value and shareholders' equity analysis.
Abivax SA American Depositary Shares - Asset Composition Analysis
Current Asset Composition (December 2025)
Abivax SA American Depositary Shares's total assets of $547.14 Million consist of 94.3% current assets and 5.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.4% |
| Accounts Receivable | $10.49 Million | 1.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.60 Million | 1.1% |
| Goodwill | $18.41 Million | 3.2% |
Asset Composition Trend (2013–2025)
This chart illustrates how Abivax SA American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Abivax SA American Depositary Shares (ABVX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abivax SA American Depositary Shares's current assets represent 94.3% of total assets in 2025, an increase from 14.6% in 2013.
- Cash Position: Cash and equivalents constituted 88.4% of total assets in 2025, up from 7.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 85.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 3.2% of total assets.
Abivax SA American Depositary Shares Competitors by Total Assets
Key competitors of Abivax SA American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Abivax SA American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.25 | 1.25 | 2.47 |
| Quick Ratio | 8.25 | 1.25 | 2.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $450.99 Million | $26.93 Million | $12.48 Million |
Abivax SA American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between Abivax SA American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.60 |
| Latest Market Cap to Assets Ratio | 18.71 |
| Asset Growth Rate (YoY) | 184.6% |
| Total Assets | $584.09 Million |
| Market Capitalization | $10.93 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Abivax SA American Depositary Shares's assets at a significant premium (18.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Abivax SA American Depositary Shares's assets grew by 184.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abivax SA American Depositary Shares (2013–2025)
The table below shows the annual total assets of Abivax SA American Depositary Shares from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $584.09 Million | +184.61% |
| 2024-12-31 | $205.23 Million | -37.25% |
| 2023-12-31 | $327.06 Million | +332.94% |
| 2022-12-31 | $75.54 Million | -30.84% |
| 2021-12-31 | $109.23 Million | +53.20% |
| 2020-12-31 | $71.30 Million | +37.83% |
| 2019-12-31 | $51.73 Million | -4.29% |
| 2018-12-31 | $54.05 Million | +0.43% |
| 2017-12-31 | $53.81 Million | -11.19% |
| 2016-12-31 | $60.60 Million | -20.55% |
| 2015-12-31 | $76.27 Million | +100.88% |
| 2014-12-31 | $37.97 Million | -1.29% |
| 2013-12-31 | $38.46 Million | -- |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more